Zymeworks earns $250 million milestone as partner Jazz wins FDA approval for Ziihera in gastric cancer
Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for two Ziihera regimens as first-line treatment of HER2-positive gastroesophageal adenocarcinoma. Zymeworks earned a $250 million milestone payment from Jazz on the approval and remains eligible for up to $1.3 billion in further milestones plus tiered royalties of 10% to 20% on Jazz's net sales. The filing does not report revenue, profit or guidance figures for the period.
Key points
- FDA approved Ziihera plus tislelizumab and chemotherapy, and Ziihera plus chemotherapy, as first-line HER2+ GEA treatments, announced August 25, 2026
- Zymeworks earned a $250 million milestone payment from Jazz; total payments from Jazz are $650 million to date
- Zymeworks remains eligible for up to $1.3 billion in additional Jazz milestones and up to $144 million in BeOne milestones
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 25, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.